Pharmacodynamic responses of F344 rats to the mouse hepatocarcinogen oxazepam in a 90-day feed study

Toxicology and Applied Pharmacology

Volumn 149, Issue 1, 1998, Pages 41-48

  Cunningham, Michael L ^a   Bucher, John R ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; OXAZEPAM;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; LIVER CARCINOGENESIS; LIVER HYPERTROPHY; LIVER WEIGHT; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SPECIES DIFFERENCE;

ANIMALIA;

EID: 0031883929     PISSN: 0041008X     EISSN: None     Source Type: Journal    
DOI: 10.1006/taap.1997.8330     Document Type: Article

References (25)

1. Alvan, G., Siwers, B., and Vessman, J. (1977). Pharmacokinetics of oxazepam in healthy volunteers. Acta Pharmicol. Toxicol. 40, 40-51.
2. Ashby, J., Brady, A., Elcombe, C. R., Elliott, B. M., Ishmael, J., Odum, J., Tugwood, J. D., Kettle, S., and Purchase, I. F. H. (1994). Mechanistically-based human hazard assessment of peroxisome proliferator-induced hepatocarcinogenesis. Hum. Exp. Toxicol. 13, S1-S117.
3. Cattley, R. C., and Popp, J. A. (1989). Differences between the promoting activities of the peroxisome proliferator WY-14,643 and phenobarbital in rat liver. Cancer Res. 49, 3246-3251.
4. Cunningham, M. L. (1996). Role of increased DNA replication in the carcinogenic risk of nonmutagenic chemical carcinogens. Mutat. Res. 365, 59-69.
5. Cunningham, M. L., Foley, J., Maronpot, R. R., and Matthews, H. B. (1991). Correlation of hepatocellular proliferation with hepatocarcinogenicity induced by the mutagenic noncarcinogen:carcinogen pair-2,6-and 2,4-diaminotoluene. Toxicol. Appl. Pharmacol. 107, 562-567.
6. Cunningham, M. L., and Matthews, H. B. (1991). Relationship of hepatocarcinogenicity and hepatocellular proliferation induced by mutagenic noncarcinogens vs carcinogens. II. 1- vs 2-Nitropropane. Toxicol. Appl. Pharmacol. 110, 505-513.
7. Cunningham, M. L., Maronpot, R. R., Thompson, M., and Bucher, J. R. (1994a). Early responses of the liver of B6C3F1 mice to the hepatocarcinogen oxazepam. Toxicol. Appl. Pharmacol. 124, 31-38.
8. Cunningham, M. L., Elwell, M. R., and Matthews, H. B. (1994b). Relationship of carcinogenicity and cellular proliferation induced by mutagenic noncarcinogens vs carcinogens. III. Organophosphate pesticides vs tris (2,3-dibromopropyl)phosphate. Fund. Appl. Toxicol. 23, 363-369.
9. Diwan, B. A., Ward, J. M., and Rice, J. M. (1989). Promotion of malignant 'embryonal' liver tumors by phenobarbital: increased incidence and shortened latency of hepatoblastomas in (DBA/2 X C57BL/6)F1 mice initiated with N-nitrosodiethylamine. Carcinogenesis 10, 1345-1348.
10. Fox, T. R., and Lahcen, R. B. (1974). Liver-cell adenomas and peliosis hepatis in mice associated with oxazepam. Res. Commun. Chem. Pathol. Pharmacol. 8, 481-188.
11. Gilman, A. G., Rail, T. W., Nies, A. S., and Taylor, P. (1990). Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed., Pergamon Press, New York.
12. Griffin, R. J., and Burka, L. T. (1993). Metabolism and elimination of oxazepam in B6C3F1 and Swiss-Webster mice. Drug Metab. Dispos. 21, 918-926.
13. Griffin, R. J., and Burka, L. T. (1995). Metabolism and elimination of oxazepam in F344 rats. Drug Metab. Dispos. 23, 232-239.
14. Griffin, R. J., Burka, L. T., and Demby, K. B. (1995a). Oxidative biotransformation of oxazepam to reactive and nonreactive products in rat, mouse and human microsomes. Hum. Exp. Toxicol. 14, 779-786.
15. Griffin, R. J., Burka, L. T., and Cunningham, M. L. (1995b). Induction of hepatic drug metabolizing enzymes by prechronic oxazepam-dosed feed treatment in B6C3F1 mice. Toxicol. Lett. 76, 251-256.
16. Griffin, R. J., Dudley, C. N., and Cunningham, M. L. (1996). Hepatic cell proliferation, enzyme activities and altered serum thyroid-stimulating hormone levels following oxazepam-dosed feed treatment in B6C3F1 mice. Fund. Appl. Toxicol. 29, 147-154.
17. Klaunig, J. E., Siglin, J. C., Schafer, L. D., Hartnett, J. A., Weghorst, Olsen, M. J., and Hampton, J. A. (1991). Correlation between species and tissue sensitivity to chemical carcinogenesis in rodents and the induction of DNA synthesis. In Chemically Induced Cell Proliferation: Implications for Risk Assessment (B. E. Butterworth, T. J. Slaga, W. Farland, and M. McClain, Eds.), pp. 185-194. Wiley-Liss, New York.
18. Maronpot, R. R., and Boorman, G. A. (1996). The contribution of the mouse in hazard identification studies. Toxicol. Pathol. 24, 726-731.
19. National Toxicology Program (NTP) (1993). Toxicology and Carcinogenesis Studies of Oxazepam in Swiss-Webster and B6C3F1 Mice. NTP TR 443. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, Research Triangle Park, NC.
20. National Toxicology Program (NTP) (1996). Toxicology and Carcinogenesis Studies of Oxazepam in F344/N Rats. NTP TR 468. U. S. Department of Health and Human Services, Public Health Service, National Institutes of Health, Research Triangle Park, NC.
21. Orlandi, F., Bamonti, F., Dini, M., Koch, M., and Jezequel, A. M. (1975). Hepatic cholesterol synthesis in man: Effect of diazepam and other drugs. Eur. J. Clin. Invest. 5, 139-146.
22. Physicians' Desk Reference, (1990). Medical Economics Co., Montvale, New Jersey.
23. Sisenwine, S. F., and Tio, C. O. (1986). The metabolic disposion of oxazepam in rats. Drug Metab. Dispos. 14, 41-45.
24. Sisenwine, S. F., Tio, C. O., Schrader, S. R., and Ruelius, H. W. (1972). The biotransformation of oxazepam (7-chloro-1,3-dihydro-3-hydroxy-5-phenyl-2H-1,4-benzodiazepine-2-one) in man, miniature swine and rat. Arzn. Forsch. 22, 682-687.
25. Smith, P. F., O'Brian, K. A., and Keenan, K. P. (1991). Evaluation of bromodeoxyuridine labeling in hepatomegaly produced by peroxisomal proliferation or P-450 induction in rodents. In Chemically Induced Cell Proliferation: Implications for Risk Assessment (B. E. Butterworth, T. J. Slaga, W. Farland, and M. McClain, Eds.), pp. 285-289. Wiley-Liss, New York.